Method for carrying out sterility test on human insulin injection containing protamine
By neutralizing and performing membrane filtration in protamine human insulin injection with sterile sodium heparin solution, combined with rinsing of sterile peptone aqueous solution, the limitations of membrane filtration method in sterile examination of protamine human insulin injection were solved, and the patient achieved the Effective sterility inspection and safety.
Patent Information
- Application Number
- CN202411222618.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art has limitations of membrane filtration in the sterile examination of protamine human insulin injection, especially due to the problem of bacterial inhibitors being intercepted by the filter membrane, and the 1% ascorbic acid solution is toxic to microorganisms, affecting the inspection effect. .
Use sterile sodium heparin solution to neutralize protamine human insulin injection, and then clear it and filter it through thin membranes. Use sterile peptone aqueous solution as the rinse solution to ensure the sterility and effectiveness of the filter membrane.
Effective sterile examination of protamine human insulin injection is achieved, avoiding the interception of antibacterial agents, and the sodium heparin solution is non-toxic to microorganisms, ensuring the accuracy and safety of the examination results.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and relates to a method for sterility testing of drugs, and specifically to a method for sterility testing of injections, and in particular to a method for sterility testing of injections containing protamine, and more specifically to a method for sterility testing of human insulin injections containing protamine. Background Art
[0002] As one of the important indicators of drug safety, drug sterility testing has always been a major issue facing drug inspection staff. Especially with the increasing development of drug dosage forms and the continuous improvement of drug standards, it is more urgent to conduct drug sterility testing in a timely and effective manner.
[0003] In the sterility inspection of injections, membrane filtration is the most effective method to eliminate the antibacterial components of drugs. However, some protamine-containing injections cannot be filtered because they contain large particles. For example, protamine human insulin injection is a suspension of protamine and human insulin. Among them, insulin is a protein hormone secreted by pancreatic β cells stimulated by endogenous or exogenous substances such as glucose, lactose, ribose, arginine, glucagon, etc. Insulin is the only hormone in the body that lowers blood sugar, and it is also the only hormone that promotes the synthesis of glycogen, fat, and protein at the same time. The mechanism of action belongs to the receptor tyrosine kinase mechanism. It is mainly used to treat diabetes and wasting diseases. The insulin injections that are widely used in the treatment of diabetes in the market are classified according to the duration of their efficacy [Norrman M, et al. Structural characterization ofinsulin NPH formulations[J]. European journal pharmaceutical sciences, 2007,30:414], mainly including: 1) ultra-short-acting; 2) short-acting (rapid-acting); 3) intermediate-acting (low-protamine zinc insulin); 4) long-acting (protamine zinc insulin); 5) premixed: short-acting and intermediate-acting are premixed and can be injected once, with a fast onset of action (30 minutes) and a duration of up to 16 to 20 hours.
[0004] In order to prolong the duration of insulin in the body, protamine insulin combined with protamine can be used. In the premixed delayed-release preparation, under neutral conditions containing a small amount of zinc ions and phenol or phenol derivatives, the negatively charged insulin combines with the positively charged protamine sulfate to form a rod-shaped white precipitate, which reduces its solubility in human body fluids and achieves the purpose of delayed release [Zhu Chenchen, Qiao Deshui, Tu Jiasheng. Determination of protamine sulfate content in protamine insulin injection by RP-HPLC. Pharmaceutical Biotechnology, 2008, 15(3):212~215]. For this reason, the 2020 edition of the Chinese Pharmacopoeia III contains three typical (intermediate-acting) protamine human insulin injection, (biphasic) protamine human insulin mixed injection (30R, of which regular human insulin accounts for 30% and protamine human insulin accounts for 70%), and (biphasic) protamine human insulin mixed injection (50R, of which regular human insulin accounts for 50% and protamine human insulin accounts for 50%). The above injection solution is usually added with about 1.5 mg / ml of m-cresol and about 0.65 mg / ml of phenol as antibacterial agents.
[0005] The above injection is a neutral sterile suspension of human insulin and protamine sulfate. Protamine sulfate is the sulfate of a strongly alkaline protein. Protamine is a low molecular weight protein rich in alkaline amino acids with an isoelectric point of 12.1. The isoelectric point of human insulin is 5.3. Human insulin and protamine sulfate combine in equal amounts to form a complex, so it appears as a white suspension in a neutral solution. The crystalline human insulin precipitates to produce a moderate effect. For protamine insulin injection, it is generally stipulated that when observed under a microscope, the crystals are rod-shaped, and the vast majority of crystals must not be less than 1μm and must not be larger than 60μm. No aggregates exist. This product cannot be filtered by membrane filtration due to the large radius of the crystal particles. To overcome this problem, When the above-mentioned injections included in the 2015 edition of the Chinese Pharmacopoeia Part II and the 2020 edition of the Chinese Pharmacopoeia Part III are subjected to sterility testing, 3 to 10 ml of the injection is usually added with 100 ml of 1% sterile ascorbic acid solution and shaken to clarify the solution, and then treated by membrane filtration, and sterility testing is carried out in accordance with the Pharmacopoeia General Chapter 1101. However, it has been found that since the sterile 1% ascorbic acid solution has a certain toxicity to microorganisms such as bacteria for sterility testing, there is a need for improvement in this method.
[0006] Document CN103063807A (Chinese patent application number 201210559162.X) discloses a method for sterility inspection of protamine-containing injection, in which heparin salt is used as a neutralizer. The method specifically comprises the following steps: adding sterile heparin salt solution to the protamine-containing injection until the solution is clarified; sterile membrane filtration; and sterility inspection. The invention solves the problem that membrane filtration cannot be used for protamine-containing injection, and provides a simple and efficient method for sterility inspection of protamine-containing injection.
[0007] Furthermore, Zhang Guanghua's paper (Zhang Guanghua, et al. Establishment of sterility test method for protamine insulin injection [J]. Chinese Modern Applied Pharmacy, 2020, 37(9):1102-1105) established a sterility test method for protamine insulin injection in detail. This method was tested for method suitability according to the 1101 Sterility Test Method of the General Rules of Part Four of the 2020 Edition of the Chinese Pharmacopoeia, and the sterility test method for protamine insulin injection included in the Pharmacopoeia was optimized. The protamine in the insulin injection was neutralized with a sodium heparin solution without microbial toxicity, so that the protamine insulin injection changed from a white suspension to a clear and transparent liquid, which was convenient for membrane filtration. In this method, the membrane filtration method was used, and all six positive control bacteria in the sterility test method suitability test were able to grow normally, thus establishing a feasible sterility test method for protamine insulin injection, providing an experimental basis for the improvement of the sterility test method for protamine human insulin-related injections. However, the present inventors have found that the above method still needs to be improved, for example, to overcome the problem of antibacterial agent being retained by the filter membrane.
[0008] Therefore, those skilled in the art still expect to have a new method to facilitate the sterility test of human insulin injection containing protamine. Summary of the invention
[0009] The object of the present invention is to provide a new method so that human insulin injection containing protamine can be accurately tested for sterility. It has been unexpectedly found that the beneficial effects of one or more aspects of the present invention can be obtained by using the method of the present invention, and the present invention is completed based on such discovery.
[0010] To this end, the present invention provides a method for sterility testing of a human insulin injection containing protamine, which comprises the following steps: 1) Add sterile heparin salt solution to human insulin injection containing protamine until the solution becomes clear; 2) Sterile membrane filtration, flushing the filter with flushing fluid; 3) Perform sterility test on the filter.
[0011] According to the method of the present invention, the heparin salt is heparin sodium or heparin calcium.
[0012] According to the method of the present invention, the heparin salt solution is a 0.9% sodium chloride solution of heparin salt.
[0013] According to the method of the present invention, the heparin salt solution is 300 mL of sterile 0.9% sodium chloride solution containing 100 mg of heparin sodium (heparin sodium 60 U / mL).
[0014] According to the method of the present invention, the heparin salt solution is added in a ratio of 100 units of heparin per 1 mg of protamine.
[0015] According to the method of the present invention, the flushing liquid is a sterile peptone aqueous solution.
[0016] According to the method of the present invention, the flushing solution is a sterile 0.1% peptone aqueous solution.
[0017] According to the method of the present invention, the flushing liquid is a pH 7.0 sterile sodium chloride-peptone buffer; for example, it is prepared as follows: 3.56g of potassium dihydrogen phosphate, 5.77g of anhydrous disodium hydrogen phosphate, 4.30g of sodium chloride, 1.00g of peptone, add 1000ml of water, dissolve at a low temperature, adjust the pH to 7.0 with phosphoric acid or sodium hydroxide if necessary, filter to clarify, package, and sterilize to obtain. Or the flushing liquid is flushing liquid y.
[0018] According to the method of the present invention, the human insulin injection containing protamine is selected from: protamine human insulin injection, protamine human insulin mixed injection such as 30R type or 50R type.
[0019] According to the method of the present invention, it comprises the following steps: taking human insulin injection containing protamine (for example, 30 vials), placing it in 0.9% sterile sodium chloride injection (for example, 300 mL) containing 60 U / ml sodium heparin, shaking until the solution is clear, membrane filtering, washing with pH 7.0 sterile sodium chloride-peptone buffer (≥300 mL per membrane), and using Staphylococcus aureus as the positive control bacteria, performing a sterility inspection in accordance with the statutory sterility inspection method (for example, the provisions of the pharmacopoeia, for example, the provisions of 1101 of the General Rules of Part Four of the 2020 Edition of the Chinese Pharmacopoeia).
[0020] Any technical feature of any aspect of the present invention or any embodiment of the aspect is also applicable to any other embodiment or any other embodiment of the aspect, as long as they do not contradict each other. Of course, when they are applicable to each other, the corresponding features can be appropriately modified if necessary. The various aspects and features of the present invention are further described below.
[0021] All documents cited in the present invention are incorporated herein by reference in their entirety, and if the meanings expressed in these documents are inconsistent with the present invention, the description of the present invention shall prevail. In addition, the various terms and phrases used in the present invention have the general meanings known to those skilled in the art. Even so, the present invention still hopes to provide a more detailed description and explanation of these terms and phrases. If the terms and phrases mentioned are inconsistent with the known meanings, the meanings expressed in the present invention shall prevail.
[0022] Various aspects of the present invention are further described below.
[0023] The insulin injections most commonly used for diabetes treatment on the current market mainly include: ① rapid-acting preparations with a fast onset and short duration; ② intermediate- or long-acting preparations with a relatively flat drug release curve and a duration of 24 h or longer; ③ biphasic insulin preparations that combine rapid-acting and intermediate-acting preparations to achieve a long duration of action [NORRMAN M, et al. Structural characterization of insulin NPH formulations [J]. Eur J Pharm Sci, 2007, 30(5): 414-423]. In the prescriptions of the sustained-release preparations of ② and ③, under neutral conditions containing a small amount of zinc ions and phenol or phenol derivatives, negatively charged insulin binds to positively charged protamine sulfate to form a white precipitate with a rod-shaped crystal form, and its solubility in human body fluids decreases, thus achieving the purpose of sustained release [ZHU C C, et al. Determination of protamine sulphate in protamine insulin injection by RP-HPLC[J]. Pharm Biotechnol (Drug Biotechnology), 2008, 15(3): 212-215]. For example, protamine zinc insulin injection is a sterilized suspension of insulin (porcine or bovine) containing protamine and zinc chloride. Each 100 U contains 1.0-1.5 mg of protamine and 0.2-0.25 mg of zinc, and it is an animal insulin preparation with a sustained-release effect [NORRMAN M, et al. Structural characterization of insulin NPH formulations [J]. Eur J Pharm Sci, 2007, 30(5): 414-423]. Due to the presence of a certain amount of protamine in the injection, the solution is generally a white or off-white suspension.The sterility test is an important method to ensure the safety of sterile preparations [CHEN L P, et al. Study on establishment and optimization of the sterility test method for itraconazole iv [J]. Pharm Biotechnol (Drug Biotechnology), 2016, 23(1): 62-64]. The sterility test methods for protamine recombinant human insulin injection, protamine zinc insulin injection, and protamine zinc insulin injection (30R) included in the Chinese Pharmacopoeia (2020 Edition) are as follows: Take this product, add 100 mL of 1% sterile ascorbic acid solution, shake to clarify the solution, and then treat it by the membrane filtration method. Check according to the law (General Rule 1101) and it should comply with the regulations. However, there is no literature report on the toxicity of 1% ascorbic acid solution to microorganisms.
[0024] This study investigated the toxicity of sterile 1% ascorbic acid solution to microorganisms and found that it has certain toxicity to the validation bacteria. According to the characteristics of the product, the neutralization effect of heparin sodium on protamine was designed to turn the white suspension into a clear and transparent liquid, which is convenient for membrane filtration. And in accordance with the regulations in the sterility test method (General Rule 1101) of the Fourth Part of the Chinese Pharmacopoeia (2020 Edition), the neutralizer and membrane filtration method were used in combination for the sterility test method suitability test. The effectiveness and toxicity of the sterile 0.9% sodium chloride solution containing 60 U / mL of heparin sodium as a neutralizer were investigated, and an effective sterility test method for insulin injection containing protamine was established. This method shows excellent effects in one or more aspects. Specific Embodiments
[0025] The following examples provided by the present invention are only for explanatory purposes and not for, nor should they be construed as limiting the present invention in any way. Those skilled in the art will recognize that routine changes and modifications can be made to the following examples without exceeding the spirit or scope of the present invention.
[0026] In particular, the present invention specifically verified the feasibility of the present invention and some other details by taking protamine human insulin injection (SJ20201018, specification 300 IU / 3 ml / vial), protamine human insulin mix injection (30R) (SJ20201008, specification 300 IU / 3 ml / vial), and protamine human insulin mix injection (50R) (SJ20201009, specification 300 IU / 3 ml / vial) as examples. The reagents used in the following examples can all be obtained commercially. The experimental methods in the following examples are all conventional methods unless otherwise specified.
[0027] The instruments used in the present invention are all conventional instruments. If not otherwise specified, the models, specifications and sources of some of the instruments used are as follows: HTY-CZ1806B sterile isolator, HTY-2000A bacteria collector, KDGB330 disposable fully enclosed triple bacteria collection incubator, i.e., KDGB330 triple enclosed sterile inspection membrane filter with a pore size of 0.45 μm, all purchased from Hangzhou Tailin Biotechnology Equipment Co., Ltd.; KB720 biochemical incubator (Binder, Germany); XG1.DMXD-0.36 electric pulsating vacuum sterilizer (Shandong Xinhua Company); Thermoelectric 1300 Series A2 biological safety cabinet (Thermo Company); YX930D electric aspirator (Shanghai Smanfeng Company).
[0028] The test samples used in this example are all conventional samples. Unless otherwise specified, the specifications and sources of some of the test samples used are as follows: Injection A: Protamine human insulin injection (SJ20201018, specification 300IU / 3ml / vial), Injection B: Protamine human insulin mixed injection (30R) (SJ20201008, specification 300IU / 3ml / vial), Injection C: Protamine human insulin mixed injection (50R) (SJ20201009, specification 300IU / 3ml / vial) The test strains used in the present invention are mainly as follows: Bacillus subtilis CMCC(B) 63501, Escherichia coli [Escherchia coli CMCC(B) 44102], Pseudomonas aeruginosa [Pseudomonas aeruginosa CMCC(B)10104], Staphylococcus aureus [Staphylococcus aureus CMCC(B)26003], Clostridium sporogenes [Clostridium sporogenes CMCC(B)64941], Candida albicans [Candida albicans CMCC(F)98001], Aspergillus niger [Aspergillus niger CMCC98003], These test strains are all from the Medical Microbiology Culture Collection Center of the China Food and Drug Inspection Institutes.
[0029] If not otherwise specified, some culture media and reagents used in the present invention and their sources are mainly as follows: thioglycollate fluid culture medium, tryptic soytone liquid culture medium, tryptic soytone agar culture medium, and Sabouraud dextrose agar culture medium were all purchased from Beijing Aoboxin Biotechnology Co., Ltd.; 0.9% sodium chloride injection was purchased from Shijiazhuang Siyao Co., Ltd.; heparin sodium was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.; ascorbic acid was purchased from Sinopharm Chemical Reagent Co., Ltd.
[0030] Other test solutions, buffer solutions or flushing solutions were prepared by yourself unless otherwise specified.
[0031] Example 1: Methodological Investigation The relevant experimental operations of this embodiment are carried out according to the method of Zhang Guanghua (Zhang Guanghua, Jiang Zhijie, Liu Wenjie. Establishment of sterility test method for protamine insulin injection [J]. Chinese Modern Applied Pharmacy, 2020, 37 (9): 1102-1105), unless otherwise specified. The pH 7.0 sterile sodium chloride-peptone buffer used as the flushing liquid in this embodiment is prepared according to the formula specified in the Chinese Pharmacopoeia by the following method: take 3.56g of potassium dihydrogen phosphate, 5.77g of anhydrous disodium hydrogen phosphate, 4.30g of sodium chloride, 1.00g of peptone, add 1000ml of water, dissolve at a low temperature, adjust pH 7.0 with phosphoric acid or sodium hydroxide if necessary, filter to clarify, dispense, and sterilize at 121°C for 15min to obtain (which can be referred to as flushing liquid x in the present invention).
[0032] 1.1. Colony preparation and counting The sterility test method of Part IV of the 2020 edition of the Chinese Pharmacopoeia (General Chapter 1101) was followed, and the results are shown in Table 1.
[0033] Table 1: Colony count results (cfu / ml)
[0034] 1.2. Culture medium suitability test For the suitability test of the culture medium used in the present invention, the sterility test was carried out according to the sterility test method of the fourth part of the Chinese Pharmacopoeia 2020 edition (General Rule 1101), and the results were in line with the pharmacopoeia standards. The sensitivity test was carried out according to the sterility test method of the fourth part of the Chinese Pharmacopoeia 2020 edition (General Rule 1101), and the results were in line with the pharmacopoeia standards.
[0035] 1.3. Interaction test between neutralizer and insulin injection This example selects the following two self-prepared neutralizers: Neutralizer M: 300 mL of sterile 0.9% sodium chloride solution containing 100 mg of heparin sodium (heparin sodium 60 U / mL), Neutralizer N: 100 mL of sterile solution containing 1% ascorbic acid used in the sterility test method included in the 2020 edition of the Chinese Pharmacopoeia.
[0036] The general preparation method of the neutralizing agent is: dissolve the materials in the specified proportion in water, filter, and sterilize at 121°C for 15 minutes.
[0037] After mixing according to the proportions in the table below, the above two neutralizers and the injection solutions containing protamine and human insulin described in the injection solutions A to C in this article can be completely clarified after a certain period of time, indicating that both neutralizer solutions are effective and can completely dissolve the suspension injection solution and smoothly pass through the sterile filter membrane. The specific results are shown in the following Table 2.
[0038] Table 2: Interaction results between neutralizer solution and protamine human insulin injection
[0039] 1.4. Toxicity test of neutralizers to microorganisms Bacterial solution group (rinsing solution): Take 10mL of pH 7.0 sterile sodium chloride-peptone buffer (rinsing solution x), add 0.1mL of the prepared test bacterial solution (300-600 cfu), mix well, and let stand for 30 minutes. Take 1mL of this bacterial solution, filter it through a membrane, and then rinse the filter membrane with pH 7.0 sterile sodium chloride-peptone buffer (rinsing solution x) (100mL per membrane), and then count bacteria, molds and yeasts according to the law (each test strain is performed separately).
[0040] Neutralizer control group: Take 10 mL of sterile 0.9% sodium chloride solution (neutralizer M) containing 60 U / mL of heparin sodium and 1% ascorbic acid sterile solution (neutralizer N), add 0.1 mL of the prepared test bacterial solution (300-600 cfu), mix well, and let stand for 30 minutes. Take 1 mL of each solution, filter through a membrane, and then rinse the filter membrane with pH 7.0 sterile sodium chloride-peptone buffer (rinsing solution x) (100 mL per membrane), and then count bacteria, molds, and yeasts according to the law (each test strain is performed separately).
[0041] For the filter membranes of Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa, stick them on trypticase soy agar plates, incubate at 33°C for 5 days, and count them; For the filter of Clostridium sporogenes, add 200 mL of thioglycollate fluid medium, culture at 33°C in the anaerobic zone for 24 h, and count; For Candida albicans and Aspergillus niger filters, stick them on Sabouraud dextrose agar plates, incubate at 23°C for 5 days, and count them; The results are shown in Table 3.
[0042] Table 3: Microbial recovery ratio after neutralization
[0043] In the above table, the flushing solution is a sterile sodium chloride-peptone buffer solution at pH 7.0, the neutralizer M is a sterile 0.9% sodium chloride solution containing 60 U / mL of heparin sodium, and the neutralizer N is a sterile solution containing 1% ascorbic acid.
[0044] In the Microbial Count Method (General Rule 1105) of Part IV of the 2020 Edition of the Chinese Pharmacopoeia, it has been pointed out that if a neutralizer or inactivator is used, a neutralizer or inactivator control group should be set up in the test to confirm its effectiveness and non-toxicity to microorganisms. The ratio of the colony count of the neutralizer or inactivator control group to the colony count of the bacterial solution control group should be within 0.5~2. From the results in Table 3 above, it can be seen that the minimum recovery rate of the recovery ratio M is 0.76, all >0.5, indicating that the solution containing 60U / mL of heparin sodium is non-toxic to microorganisms and is suitable for use as a neutralizer. The bacterial recovery ratios in the recovery ratio N are all <0.5, the minimum recovery rate is only 0.07, and the fungal recovery rates are all >0.71, indicating that the solution containing 1% ascorbic acid is toxic to bacteria and is not suitable as a neutralizer.
[0045] 1.5. Test on suitability of membrane filtration method Take 30 test samples (injection A, 3 ml / vial), place in 300 mL of 0.9% sterile sodium chloride injection containing 60 U / ml heparin sodium, shake until the solution is clear, filter through a membrane, rinse with pH 7.0 sterile sodium chloride-peptone buffer (300 mL per membrane), and perform the following tests according to the sterility test method of Part IV of the 2020 edition of the Chinese Pharmacopoeia (General Rule 1101): test sample group, negative control group, positive control bacteria containing the test sample, and positive bacteria control. The results are shown in Tables 4 and 5.
[0046] Table 4: Culture results of test group and negative control group
[0047] Table 5: Positive control bacteria culture results
[0048] The above results show that both the test sample group and the negative control group have no bacterial growth, and the test bacteria in each filter of the test sample positive bacteria control group grow well compared with the positive bacteria control group, indicating that the test amount of the test sample has no antibacterial effect or its antibacterial effect is negligible under the test conditions, and the above inspection method is feasible. Staphylococcus aureus was selected as the positive control bacteria according to the characteristics of the test sample. In addition, the samples of injection B and injection C were subjected to parallel experiments in the same way, and the results were consistent with the above Tables 4 and 5.
[0049] Example 2: Methodological Investigation This example is basically carried out with reference to the method of Example 1 of the present invention, with the main difference being that the formula of the flushing liquid used is changed. The preparation method of the flushing liquid used in this example is as follows: 3.14 g of sodium dihydrogen phosphate (anhydrous), 5.77 g of disodium hydrogen phosphate anhydrous, 4.30 g of sodium chloride, 5 g of propylene glycol, and 1.00 g of peptone are added to 1000 ml of water and dissolved at a low temperature. If necessary, the pH value is adjusted to 7.0 with phosphoric acid or sodium hydroxide, filtered to clarify, packaged, and sterilized at 121°C for 15 min. The flushing liquid is referred to as flushing liquid y in the present invention.
[0050] 2.1. Colony preparation and counting The sterility test method of Part IV of the 2020 edition of the Chinese Pharmacopoeia (General Chapter 1101) was followed, and the results are shown in Table 1.
[0051] Table 6: Colony count results (cfu / ml)
[0052] 2.2. Suitability test of culture medium For the suitability test of the culture medium used in the present invention, the sterility test was carried out according to the sterility test method of the fourth part of the Chinese Pharmacopoeia 2020 edition (General Rule 1101), and the results were in line with the pharmacopoeia standards. The sensitivity test was carried out according to the sterility test method of the fourth part of the Chinese Pharmacopoeia 2020 edition (General Rule 1101), and the results were in line with the pharmacopoeia standards.
[0053] 2.3. Interaction test between neutralizer and insulin injection This example selects the following two self-prepared neutralizers: Neutralizer M: 300 mL of sterile 0.9% sodium chloride solution containing 100 mg of heparin sodium (heparin sodium 60 U / mL), Neutralizer N: 100 mL of sterile solution containing 1% ascorbic acid used in the sterility test method included in the 2020 edition of the Chinese Pharmacopoeia.
[0054] The general preparation method of the neutralizing agent is: dissolve the materials in the specified proportion in water, filter, and sterilize at 121°C for 15 minutes.
[0055] After mixing according to the proportions in the table below, the above two neutralizers and the injection solutions containing protamine and human insulin described in the injection solutions A to C in this article can be completely clarified after a certain period of time, indicating that both neutralizer solutions are effective and can completely dissolve the suspension injection solution and smoothly pass through the sterile filter membrane. The specific results are shown in the following Table 2.
[0056] Table 7: Interaction results of neutralizer solution and protamine human insulin injection
[0057] 2.4. Toxicity test of neutralizers to microorganisms Bacterial solution group (rinsing solution): Take 10 mL of the rinsing solution y of Example 2, add 0.1 mL of the prepared test bacterial solution (300-600 cfu), mix well, and let stand for 30 minutes. Take 1 mL of the bacterial solution, filter through the membrane, then rinse the filter membrane with the rinsing solution y (100 mL per membrane), and then count the bacteria, molds and yeasts according to the law (each test strain is performed separately).
[0058] Neutralizer control group: Take 10 mL of sterile 0.9% sodium chloride solution containing 60 U / mL of heparin sodium (neutralizer M) and 1% ascorbic acid sterile solution (neutralizer N), add 0.1 mL of the prepared test bacterial solution (300-600 cfu), mix well, and let stand for 30 minutes. Take 1 mL of each solution, filter through a membrane, then rinse the filter membrane with rinse solution y (100 mL per membrane), and then count bacteria, molds, and yeasts according to the law (each test strain is performed separately).
[0059] For the filter membranes of Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa, stick them on trypticase soy agar plates, incubate at 33°C for 5 days, and count them; For the filter of Clostridium sporogenes, add 200 mL of thioglycollate fluid medium, culture at 33°C in the anaerobic zone for 24 h, and count; For Candida albicans and Aspergillus niger filters, stick them on Sabouraud dextrose agar plates, incubate at 23°C for 5 days, and count them; The results are shown in Table 3.
[0060] Table 8: Microbial recovery ratio after neutralization
[0061] In the above table, the flushing solution is flushing solution y, the neutralizing agent M is a sterile 0.9% sodium chloride solution containing 60 U / mL of heparin sodium, and the neutralizing agent N is a sterile solution containing 1% ascorbic acid.
[0062] From the results in Table 8 above, it can be seen that the minimum recovery rate of the recovery ratio M is 0.96, all of which are >0.5 and close to 1.0, indicating that the solution containing 60U / mL of sodium heparin is non-toxic to microorganisms and is suitable for use as a neutralizer; especially for Clostridium sporogenes, Aspergillus niger and Pseudomonas aeruginosa, it increased from about 0.8 or even less than 0.8 to about 1.0. Although the results of the three in Table 3 are all greater than 0.5, there is still a large gap from 1.0. The bacterial recovery ratios in the recovery ratio N are all <0.5, the minimum recovery rate is only 0.08, and the fungal recovery rates are all >0.65, indicating that the solution containing 1% ascorbic acid is toxic to bacteria and is not suitable for use as a neutralizer.
[0063] 2.5. Test on suitability of membrane filtration method Take 30 test samples (injection A, 3 ml / vial), place in 300 mL of 0.9% sterile sodium chloride injection containing 60 U / ml heparin sodium, shake until the solution is clear, filter through a membrane, rinse with flushing solution y (300 mL per membrane), and perform the following tests according to the sterility test method of Part IV of the 2020 edition of the Chinese Pharmacopoeia (General Rule 1101): test sample group, negative control group, positive control bacteria containing the test sample, and positive bacteria control. The results are shown in Tables 9 and 10.
[0064] Table 9: Culture results of test group and negative control group
[0065] Table 10: Positive control bacteria culture results
[0066] The above results show that both the test sample group and the negative control group have no bacteria growth, and the test bacteria in each filter of the test sample positive bacteria control group grow well compared with the positive bacteria control group, indicating that the test amount of the test sample has no antibacterial effect under the test conditions or its antibacterial effect can be ignored, and the above inspection method is feasible; Staphylococcus aureus is selected as the positive control bacteria according to the characteristics of the test sample. In addition, the samples of injection B and injection C were subjected to parallel experiments with the method of the above Example 2, and the results are consistent with the above Tables 9 and 10. The above Example 2 used a flushing solution y with added sodium dihydrogen phosphate and propylene glycol. The results in Table 8 show that the recovery rates of the seven microorganisms are all close to 1.0, which is significantly better than the results of using conventional flushing solution x in Table 3. It is speculated that this result may be related to the addition of sodium dihydrogen phosphate and propylene glycol in the flushing solution. To verify this hypothesis, the present invention conducts the following supplementary experiments referred to as Example 2a and Example 2b. Example 2a: Referring to the method of Example 2, the only difference is that the sodium dihydrogen phosphate in the washing liquid y is replaced by 3.56 g of potassium dihydrogen phosphate. The results show that except for the obvious difference in the recovery ratio M in Table 8 of Example 2, the other results are basically the same as those in Example 2. The recovery ratios M of the seven microorganisms are: 0.99, 1.02, 0.94, 0.81, 1.08, 0.80, and 0.77 (close to the results in Table 3), indicating that the recovery ratios M of Clostridium sporogenes, Aspergillus niger, and Pseudomonas aeruginosa are far from 0.1. Example 2b: Referring to the method of Example 2, the only difference is that propylene glycol is not added to the washing liquid y used. The results show that, except for the obvious difference in the recovery ratio M in Table 8 of Example 2, the other results are basically the same as those in Example 2. The recovery ratios M of the seven microorganisms are 1.01, 0.98, 0.95, 0.80, 1.06, 0.78, and 0.79 (close to the results in Table 3), indicating that the recovery ratios M of Clostridium sporogenes, Aspergillus niger, and Pseudomonas aeruginosa are far from 0.1. In addition, samples of injection B and injection C were tested using the method of Example 2. In the results characterized by the recovery ratio M shown in Table 8, the recovery ratio M of injection B was in the range of 0.97 to 1.08, for example, the recovery ratio M of Clostridium sporogenes was 0.99, and the recovery ratio M of injection C was in the range of 0.96 to 1.05, for example, the recovery ratio M of Clostridium sporogenes was 1.02. There was no significant difference in the recovery ratio N of injection B and injection C compared with the results in Table 8, for example, the recovery ratios N of injection B and injection C were 0.33 and 0.29, respectively; these results indicate that the method of Example 2 of the present invention is also applicable to injection B and injection C.
[0067] The present invention can establish a method for sterility inspection of insulin injection containing protamine through Examples 1 and 2, the method is: take 30 vials of this product, place them in 300 mL of 0.9% sterile sodium chloride injection containing 60 U / ml heparin sodium, shake until the solution is clear, filter through a membrane, rinse with pH 7.0 sterile sodium chloride-peptone buffer (each membrane ≥ 300 mL), use Staphylococcus aureus as the positive control bacteria, and inspect according to the law (General Rules 1101 of Part IV of the 2020 Edition of the Chinese Pharmacopoeia), which should comply with the regulations. The above-mentioned flushing liquid is preferably the flushing liquid used in Example 2, namely, flushing liquid y, which is prepared according to the following method: take 3.14g of anhydrous sodium dihydrogen phosphate, 5.77g of anhydrous disodium hydrogen phosphate, 4.30g of sodium chloride, 5g of propylene glycol, and 1.00g of peptone, add 1000ml of water, dissolve at slight temperature, adjust the pH to 7.0 with phosphoric acid or sodium hydroxide if necessary, filter to clarify, package, and sterilize to obtain.
[0068] The preparation method of the sterile solution containing 60 U / ml of heparin sodium of the present invention is as follows: weigh 100 mg of heparin sodium, add it to 300 mL of 0.9% sodium chloride solution, and sterilize at 121° C. for 15 minutes to obtain the solution.
[0069] As is known to all, the Chinese Pharmacopoeia stipulates that in the sterility test process, if surfactants, inactivators, neutralizers and other reagents are needed, their effectiveness should be proved and they should be non-toxic to microorganisms. In the process of methodological applicability, the effectiveness of the neutralizer is easy to understand. For the present invention, it is mainly to dissolve the suspended particles, but the neutralizer should be required to be non-toxic to microorganisms. There is no clear provision in the Chinese Pharmacopoeia. At present, it is basically to add a neutralizer control group to observe whether the microorganism grows or not. There is also a way to add microorganisms to the liquid containing the neutralizer in accordance with the methodological applicability of the microbial limit. After a certain period of action, the survival rate of the microorganism is detected [ZHANG GH, et al. Establishment of the sterility test method for Minocycline Hydrochloride Ointment [J]. Cap Food Med (Capital Food and Medicine), 2019, 26 (2): 162-164]. The inventors believe that the latter quantitative method is more scientific and reasonable than the former qualitative method. This study used sodium heparin as a neutralizing agent. Through the latter's quantitative test, it was found that the recovery rates of various microorganisms were all >0.5, which well demonstrated that the sodium heparin solution had no toxicity to the microorganisms under investigation. At the same time, the bacterial recovery rates of the 1% ascorbic acid solution under investigation were all <0.5, indicating that it had certain toxicity to bacteria. However, if only the neutralizer control group was added and a qualitative method was used for the investigation, when the positive bacteria value was large, the bacteria in the liquid culture medium might also grow well, which could not truly reflect its toxicity to microorganisms.
[0070] According to the requirements of the 1101 Sterility Test Method of the General Rules of Part IV of the 2020 Chinese Pharmacopoeia, the sterility test method includes direct inoculation method and membrane filtration method. Since the membrane filtration method uses a large number of sampling and bacteria collection methods, it is representative, not easy to miss detection, and the instrument is simple to operate. The system is a fully closed filtration system, which avoids the contamination of exogenous bacteria during the operation and has little impact on the reliability of the test results. However, some varieties need to find a neutralizer because of their own antibacterial effect. Some need to find a corresponding diluent because of the excipients. Some need to find a substance to clarify because they are turbid liquids. Protamine-containing insulin injection contains about 1.0~1.5mg of protamine per 100U [DING XL, et al. Study on determination of protamine sulfate in protamine zine insulin injection [J]. Chin J Pharm Anal (Journal of Drug Analysis), 2012, 32(4): 679-681]. Each 1mg of protamine can neutralize the anticoagulant effect of heparin>100U. The inspection quantity for one sterility test is 30 vials, and the total amount of protamine contained is about 90-180 mg. The experimental design selects 300 mL of sterile 0.9% sodium chloride solution containing 60 U / ml of sodium heparin as a diluent, which is sufficient to neutralize the protamine contained in the insulin injection, so that the white suspension becomes a clear and transparent liquid, which is convenient for membrane filtration, eliminates the antibacterial effect of the preservative contained in the protamine insulin injection, and is convenient for observing the results. In this sense, the main function of the sodium heparin sterile solution of the present invention is to change the suspension into a clear solution that can pass through the filter membrane, so that various substances including preservatives are filtered below the filter membrane, while large-particle microorganisms are retained on the filter membrane by the microporous filter membrane. In the sterility test method of protamine human insulin injection, protamine human insulin mixed injection (R30) and protamine human insulin mixed injection (R50) recorded in the 2020 edition of the Chinese Pharmacopoeia, the effect of the 1% ascorbic acid sterile solution 100mL used is to increase the solubility of protamine under acidic conditions, but as mentioned above, it is found by judging the quantitative recovery rate of bacteria that 1% ascorbic acid sterile solution has certain toxicity to bacteria. The pH value of 1% ascorbic acid sterile solution is about 2.72, and it is preliminarily believed that its toxicity to bacteria may be related to its low pH value. Because 1% ascorbic acid sterile solution is toxic to bacteria, it does not meet the general requirements of the Chinese Pharmacopoeia for diluents and neutralizers. Therefore, the present invention develops a method for sterility inspection of insulin injection containing protamine, which has very important practical significance.
[0071] The above-described embodiments are only preferred embodiments for fully illustrating the present application, and the protection scope of the present application is not limited thereto. Equivalent substitutions or changes made by technicians in the technical field based on the present application are all within the protection scope of the present application. The protection scope of the present application shall be subject to the claims.
Claims
1. A method for sterility testing of a human insulin injection containing protamine, comprising the following steps: 1) Add sterile heparin salt solution to human insulin injection containing protamine until the solution becomes clear; 2) Sterile membrane filtration, flushing the filter with flushing fluid; 3) Perform sterility test on the filter.
2. The method according to claim 1, wherein the heparin salt is heparin sodium or heparin calcium.
3. The method according to claim 1, wherein the heparin salt solution is a 0.9% sodium chloride solution of heparin salt.
4. The method according to claim 1, wherein the heparin salt solution is 300 mL of a sterile 0.9% sodium chloride solution containing 100 mg of heparin sodium (heparin sodium 60 U / mL).
5. The method according to claim 1, wherein the heparin salt solution is added in a ratio of 100 units of heparin per 1 mg of protamine.
6. The method according to claim 1, wherein the flushing liquid is a sterile peptone aqueous solution.
7. The method according to claim 1, wherein the flushing solution is a sterile 0.1% peptone aqueous solution.
8. The method according to claim 1, wherein the flushing liquid is a sterile sodium chloride-peptone buffer solution at pH 7.0; for example, it is prepared as follows: 3.56 g of potassium dihydrogen phosphate, 5.77 g of anhydrous disodium hydrogen phosphate, 4.30 g of sodium chloride, 1.00 g of peptone, add 1000 ml of water, dissolve at lukewarm temperature, adjust the pH to 7.0 with phosphoric acid or sodium hydroxide if necessary, filter to clarify, package, and sterilize to obtain the product.
9. The method according to claim 1, wherein the human insulin injection containing protamine is selected from: protamine human insulin injection, protamine human insulin mixed injection such as 30R type or 50R type.
10. The method according to claim 1, comprising the steps of: taking a human insulin injection containing protamine, placing it in a 0.9% sterile sodium chloride injection (e.g., 300 mL) containing 60 U / ml heparin sodium, shaking until the solution is clear, filtering through a membrane, washing with a pH 7.0 sterile sodium chloride-peptone buffer (≥ 300 mL per membrane), and using Staphylococcus aureus as a positive control bacterium to perform a sterility test in accordance with the specifications of the statutory sterility test method.
Citation Information
Cited By
Non-toxicity verification method of medical sterile dissolving agent
CN119351517A
